Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 203

1.

Eculizumab in acute recurrence of thrombotic microangiopathy after renal transplantation.

Hadaya K, Ferrari-Lacraz S, Fumeaux D, Boehlen F, Toso C, Moll S, Martin PY, Villard J.

Am J Transplant. 2011 Nov;11(11):2523-7. doi: 10.1111/j.1600-6143.2011.03696.x. Epub 2011 Aug 10.

2.

Postpartum thrombotic microangiopathy revealed as atypical hemolytic uremic syndrome successfully treated with eculizumab: a case report.

Kourouklaris A, Ioannou K, Athanasiou I, Panagidou A, Demetriou K, Zavros M.

J Med Case Rep. 2014 Sep 14;8:307. doi: 10.1186/1752-1947-8-307.

3.

Thrombotic microangiopathy in systemic lupus erythematosus: efficacy of eculizumab.

El-Husseini A, Hannan S, Awad A, Jennings S, Cornea V, Sawaya BP.

Am J Kidney Dis. 2015 Jan;65(1):127-30. doi: 10.1053/j.ajkd.2014.07.031. Epub 2014 Nov 15.

PMID:
25446020
4.

Eculizumab improves posttransplant thrombotic microangiopathy due to antiphospholipid syndrome recurrence but fails to prevent chronic vascular changes.

Canaud G, Kamar N, Anglicheau D, Esposito L, Rabant M, Noël LH, Guilbeau-Frugier C, Sberro-Soussan R, Del Bello A, Martinez F, Zuber J, Rostaing L, Legendre C.

Am J Transplant. 2013 Aug;13(8):2179-85. doi: 10.1111/ajt.12319. Epub 2013 Jun 13.

5.

Eculizumab for the treatment of de novo thrombotic microangiopathy post simultaneous pancreas-kidney transplantation--a case report.

Chandran S, Baxter-Lowe L, Olson JL, Tomlanovich SJ, Webber A.

Transplant Proc. 2011 Jun;43(5):2097-101. doi: 10.1016/j.transproceed.2011.02.064.

PMID:
21693335
6.

Thrombotic Microangiopathy as a Cause of Chronic Kidney Transplant Dysfunction: Case Report Demonstrating Successful Treatment with Eculizumab.

Iqbal Z, Wood K, Carter V, Goodship TH, Brown AL, Sheerin NS.

Transplant Proc. 2015 Sep;47(7):2258-61. doi: 10.1016/j.transproceed.2015.08.004.

PMID:
26361694
7.

Insights from the use in clinical practice of eculizumab in adult patients with atypical hemolytic uremic syndrome affecting the native kidneys: an analysis of 19 cases.

Fakhouri F, Delmas Y, Provot F, Barbet C, Karras A, Makdassi R, Courivaud C, Rifard K, Servais A, Allard C, Besson V, Cousin M, Châtelet V, Goujon JM, Coindre JP, Laurent G, Loirat C, Frémeaux-Bacchi V.

Am J Kidney Dis. 2014 Jan;63(1):40-8. doi: 10.1053/j.ajkd.2013.07.011. Epub 2013 Sep 8.

PMID:
24021908
8.

Cytomegalovirus-induced thrombotic microangiopathy after renal transplant successfully treated with eculizumab: case report and review of the literature.

Java A, Edwards A, Rossi A, Pandey R, Gaut J, Delos Santos R, Miller B, Klein C, Brennan D.

Transpl Int. 2015 Sep;28(9):1121-5. doi: 10.1111/tri.12582. Epub 2015 Apr 24. Review.

PMID:
25864519
9.

Eculizumab in the treatment of atypical hemolytic uremic syndrome in infants.

Ariceta G, Arrizabalaga B, Aguirre M, Morteruel E, Lopez-Trascasa M.

Am J Kidney Dis. 2012 May;59(5):707-10. doi: 10.1053/j.ajkd.2011.11.027. Epub 2011 Dec 23.

PMID:
22196848
10.

Eculizumab for drug-induced de novo posttransplantation thrombotic microangiopathy: A case report.

Safa K, Logan MS, Batal I, Gabardi S, Rennke HG, Abdi R.

Clin Nephrol. 2015 Feb;83(2):125-9. doi: 10.5414/CN108163.

PMID:
24495904
11.

Antiphospholipid syndrome in renal transplantation.

Barbour TD, Crosthwaite A, Chow K, Finlay MJ, Better N, Hughes PD, Cohney SJ.

Nephrology (Carlton). 2014 Apr;19(4):177-85. doi: 10.1111/nep.12217. Review.

PMID:
24548061
12.

Use of Eculizumab in Patients With Allogeneic Stem Cell Transplant-Associated Thrombotic Microangiopathy: A Study From the SFGM-TC.

de Fontbrune FS, Galambrun C, Sirvent A, Huynh A, Faguer S, Nguyen S, Bay JO, Neven B, Moussi J, Simon L, Xhaard A, Resche-Riggon M, O'Meara A, Fremeaux-Bacchi V, Veyradier A, Socié G, Coppo P, de Latour RP.

Transplantation. 2015 Sep;99(9):1953-9. doi: 10.1097/TP.0000000000000601.

PMID:
25651309
13.

Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome.

Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, Bingham C, Cohen DJ, Delmas Y, Douglas K, Eitner F, Feldkamp T, Fouque D, Furman RR, Gaber O, Herthelius M, Hourmant M, Karpman D, Lebranchu Y, Mariat C, Menne J, Moulin B, Nürnberger J, Ogawa M, Remuzzi G, Richard T, Sberro-Soussan R, Severino B, Sheerin NS, Trivelli A, Zimmerhackl LB, Goodship T, Loirat C.

N Engl J Med. 2013 Jun 6;368(23):2169-81. doi: 10.1056/NEJMoa1208981.

14.

Eculizumab therapy in children with severe hematopoietic stem cell transplantation-associated thrombotic microangiopathy.

Jodele S, Fukuda T, Vinks A, Mizuno K, Laskin BL, Goebel J, Dixon BP, Teusink A, Pluthero FG, Lu L, Licht C, Davies SM.

Biol Blood Marrow Transplant. 2014 Apr;20(4):518-25. doi: 10.1016/j.bbmt.2013.12.565. Epub 2013 Dec 25.

15.

Eculizumab: safety and efficacy after 17 months of treatment in a renal transplant patient with recurrent atypical hemolytic-uremic syndrome: case report.

Châtelet V, Lobbedez T, Frémeaux-Bacchi V, Ficheux M, Ryckelynck JP, Hurault de Ligny B.

Transplant Proc. 2010 Dec;42(10):4353-5. doi: 10.1016/j.transproceed.2010.09.125.

PMID:
21168697
16.

Tailored eculizumab therapy in the management of complement factor H-mediated atypical hemolytic uremic syndrome in an adult kidney transplant recipient: a case report.

Xie L, Nester CM, Reed AI, Zhang Y, Smith RJ, Thomas CP.

Transplant Proc. 2012 Dec;44(10):3037-40. doi: 10.1016/j.transproceed.2012.07.141.

PMID:
23195022
17.

Renal thrombotic microangiopathy in systemic lupus erythematosus: clinical correlations and long-term renal survival.

Bridoux F, Vrtovsnik F, Noël C, Saunier P, Mougenot B, Lemaitre V, Dracon M, Lelièvre G, Vanhille P.

Nephrol Dial Transplant. 1998 Feb;13(2):298-304. Erratum in: Nephrol Dial Transplant 1998 May;13(5):1328.

PMID:
9509438
18.

Association of thrombotic microangiopathy and intimal hyperplasia with bleeding post-renal biopsy in antiphospholipid antibody-positive patients.

Jordan N, Chaib A, Sangle S, Tungekar F, Sabharwal T, Abbs I, Khamashta M, D'Cruz D.

Arthritis Care Res (Hoboken). 2014 May;66(5):725-31. doi: 10.1002/acr.22200.

19.

Eculizumab long-term therapy for pediatric renal transplant in aHUS with CFH/CFHR1 hybrid gene.

Román-Ortiz E, Mendizabal Oteiza S, Pinto S, López-Trascasa M, Sánchez-Corral P, Rodríguez de Cordoba S.

Pediatr Nephrol. 2014 Jan;29(1):149-53. doi: 10.1007/s00467-013-2591-8. Epub 2013 Aug 24.

PMID:
23982707
20.

Successful long-term treatment of TMA with eculizumab in a transplanted patient with atypical hemolytic uremic syndrome due to MCP mutation.

Reuter S, Heitplatz B, Pavenstädt H, Suwelack B.

Transplantation. 2013 Nov 27;96(10):e74-6. doi: 10.1097/01.TP.0000435705.63428.1f. No abstract available.

PMID:
24247905
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk